Botanix Pharmaceuticals Limited (ASX: BOT) 宣布与Piramal Pharma Solutions建立重要合作伙伴关系。根据协议，Piramal将正式启动溴化索夫溴铵（sofpironium bromide）的开发服务，该活性药物成分（API）是Botanix旗下创新疗法Sofdra®的核心成分。
此次合作标志着Piramal将成为溴化索夫溴铵的替代商业供应商，为Botanix提供关键原料的供应链保障。这一战略布局不仅强化了Sofdra®产品的生产弹性，更彰显了Botanix推进该疗法商业化进程的决心。
作为专注于皮肤病创新疗法的研发企业，Botanix通过此次合作进一步优化了其供应链体系。双方案担的协同合作，将为Sofdra®未来的市场推广奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.